Bruce Koch

Executive Director, Medical Affairs at Portola Pharmaceuticals
AstraZeneca
Wilmington, Delaware, United States

Presentation(s):

• OC 31.2 - Andexanet Alfa Is Associated With Lower In-Hospital Mortality Compared To 4-Factor Prothrombin Complex Concentrate In Patients With Factor Xa Inhibitor–Related Major Bleeding

  Monday, June 26, 2023
  11:00 – 11:15 ET